On August 6 and August 31, 2021, a phase IIa clinical trial sub center kick-off meeting of class 1 innovative drug antinotriol injection of Guangzhou saipute Medical Technology Co., Ltd. was successfully held in the Department of Neurology of Zhujiang Hospital of Southern Medical University (Fig. 1) and the Department of Neurology of Sun Yat Sen Memorial Hospital of Sun Yat sen University (Fig. 2). The trial is a randomized, double-blind, placebo-controlled clinical study to explore the safety and efficacy of antinotriol injection in the treatment of acute ischemic stroke (CDE website registration No.: ctr20192127). The successive launch of the sub centers of Zhujiang Hospital and Zhongshan Second Hospital marks that the national multi center research with Beijing Temple of Heaven hospital as the team leader has entered the stage of comprehensive launch and entry. This study will provide key clinical evidence for further confirming the safety of antinotriol in human body, especially in patients with central nervous system diseases, and verifying its neuroprotective mechanism and efficacy. The test is expected to take 18 months, and the research data will be published from the end of 2022 to the beginning of 2023. "Triol injection" is the core R & D product of Sept. The intended indication is ischemic stroke. It is a project supported by the national 13th five year plan for the creation of major new drugs. The phase I clinical trial was completed in Peking Union Medical College Hospital in 2017. The results show that the product has good pharmacokinetic characteristics, good tolerance and high safety. At present, Sept is comprehensively promoting the phase IIa clinical trial of "antinotriol injection".

The national researchers' meeting of "phase IIa clinical trial of antinotriol injection in the treatment of acute ischemic stroke" was successfully held at the National Clinical Medical Research Center for neurological diseases of Beijing Tiantan Hospital Affiliated to Capital Medical University on the morning of June 2, 2021, and was successfully concluded on the same day. "Antinotriol injection" is the core R & D product of Sept. The intended indication is ischemic stroke. It is a project supported by the national 13th five year plan for the creation of major new drugs. Phase I clinical trial has been completed in Peking Union Medical College Hospital. The results show that the product has good pharmacokinetic characteristics, good tolerance and high safety. At present, Sept is promoting in an all-round way Phase IIa clinical trial of "antinotriol injection". In order to coordinate the research strength of various clinical units and ensure excellent research quality, this "antinotriol injection" is decided to be held after consultation among the researcher unit, the sponsor and the supervision organization National clinical protocol seminar for researchers. The main expert teams participating in this meeting include the president of Beijing Tiantan Hospital and the research project leader (PI) Professor Wang Yongjun and his research and management team, Lin Suizhen, general manager of Guangzhou saipute Medical Technology Co., Ltd., her R & D management team, CRO, Wu Haibo, chairman of Beijing jingchengtong Medical Technology Co., Ltd. and his team. The other four sub centers of the project participated in the meeting online: Professor song Haiqing and his research team from Xuanwu Hospital of Capital Medical University The research and management team includes Professor Chen Huisheng and his research and management team of the General Hospital of the northern theater of the Chinese people's Liberation Army, Professor Wang Yidong and his research and management team of Sun Yat Sen Memorial Hospital of Sun Yat sen University, Professor Wang Qing and his research and management team of Zhujiang Hospital of Southern Medical University. Professor Li Shuya of Beijing Tiantan Hospital presided over the meeting. General manager Lin Suizhen, the sponsor, delivered a welcome speech. Professor Li Shuya introduced the phase IIa clinical trial scheme of antinotriol injection and pointed out that this study is a prospective, multicenter, randomized, double-blind, placebo parallel controlled clinical trial of antinotriol injection, aiming to preliminarily explore the treatment of acute cerebral infarction with antinotriol injection Ischemic stroke (AIS) Professor Zhao Xingquan, director of the Department of Neurology of Beijing Tiantan Hospital, introduced the important clinical medical value and innovation of the project. This study focuses on solving the clinical urgent needs of severe patients with large-area cerebral infarction. These patients have developed rapidly, and have lost the opportunity to rescue thrombolysis and thrombectomy, mortality and mortality The disability rate is very high, and effective therapeutic drugs are urgently needed in clinic. At present, there are no reports on clinical trials for this kind of severe patients worldwide, which is extremely challenging. He very much looks forward to antinotriol injection to meet the clinical needs. Then, Professor Liu Yaou, director of imaging department of Beijing Tiantan Hospital, and Dr. Qi Nan, national imaging center, introduced the impact of the project Technical scheme of image acquisition and interpretation. The experts attending the meeting believed that the sponsor Guangzhou Sept could select such challenging clinical indications, indicating that the sponsor was full of confidence in the efficacy of antinotriol injection. The research units, imaging, statistics and supervision units participating in the meeting said that they would work together with the sponsor to successfully complete this clinical trial of great significance. Finally, Professor Yan Guangmei, chief scientist of Sept, delivered a concluding speech.

Equipment bidding document - bidding announcement for procurement of 12 cup automatic dissolution instrument.pdf

On May 23, 2021, Zhang Longjiang, deputy secretary of Fangzi District Party committee and head of Fangzi District, Weifang City, Shandong Province, together with the leading group of the district government, visited the company to investigate and understand the company's research projects, and conducted an in-depth discussion on the innovative blood lipid health management model set around the company's products to be listed. At the meeting, Wang Wei, chairman of the board of directors of the company, Yan Guangmei, chief scientist, Lin Suizhen, general manager and Chen Jiesi, Minister of business development department, gave a detailed introduction to the company, team and project. The company focuses on the creation of new drugs for major cardiovascular and cerebrovascular diseases and central nervous system diseases. In combination with the government's advocacy of "prevention of diseases" and the urgent needs of the market, the company has developed safe and effective auxiliary lipid-lowering health products around the primary prevention and rehabilitation of cardiovascular and cerebrovascular diseases, and created a unique lipid health management model, which has been highly praised by the leaders of Fangzi District government. Zhang Longjiang district chief mentioned that the ultimate goal of "healthy Weifang, healthy China" is not only to provide the highest level of medical equipment, but to keep all residents healthy and free from diseases through policy guidance and education, which is why it is very important to go deep into the grass-roots health management. Zhang Longjiang district head made highly consistent comments and questions on the company's research projects and the current medical situation in China. Professor Yan Guangmei answered Zhang Longjiang's questions one by one. The meeting was held in a harmonious and warm atmosphere. Through this in-depth and wide-ranging meeting, the two sides carried out the health management of national blood lipid control, set up a health consultation and publicity mode with the characteristics of "people's livelihood project", and build a "blood lipid health management center" pioneered in China In order to control the level of people's blood lipids, reduce the incidence of cardiovascular and cerebrovascular events and medical expenses, we responded positively to the "healthy China 2030" proposed by general secretary Xi Jinping. Finally, Zhang Longjiang district chief highly agreed with the company's future development plan and expressed his hope for future cooperation.

On April 23, 2021, a phase IIa clinical trial kick-off meeting of class 1 innovative drug antinotriol injection of Guangzhou saipute Medical Technology Co., Ltd. was successfully held in the Department of Neurology of the army characteristic medical center of the Chinese people's Liberation Army (Chongqing Daping Hospital). The trial will be undertaken by Professor Zhang Meng of NCU of Daping Hospital. It is a randomized, double-blind and placebo-controlled clinical study aimed at exploring the safety and effectiveness of antinotriol injection combined with intravascular thrombectomy in the treatment of acute ischemic stroke (registration number of drug clinical trial registration and information publicity platform: ctr20192118). This study will provide key clinical evidence for further confirming the safety of antinotriol in human body, especially in patients with central nervous system diseases, and verifying its neuroprotective mechanism and efficacy. The trial is expected to take 18 months and the research data will be published in mid-2022.